Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-751 · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| ABT-751 | DRUG | - |
Inclusion Criteria * Stage IIIB or IV non-small cell lung cancer. * Recurrent tumor following treatment with paclitaxel or docetaxel. * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney and liver function. Exclusion Criteria * Pregnant or breast feeding. * Anti-tu...
Top 20 of 87 competitors
ABT-751 is an investigational oral small molecule that has been studied in several solid tumor types: non-small cell lung cancer, colorectal cancer, renal cell cancer, and recurrent breast cancer after taxane therapy. It is not an approved therapy; all clinical work to date has been in Phase 2 trials in oncology.
ABT-751 targets tubulin, binding the beta-tubulin subunits TUBB1, TUBB3, TUBB4A, TUBB4B, TUBB8, and TUBB. It acts as a tubulin inhibitor, interfering with microtubule dynamics in dividing cells. This mechanism is distinct from that of taxanes, which also act on tubulin but at a different binding site.
ABT-751 was developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott sponsored the Phase 2 clinical program evaluating the compound across multiple solid tumor indications in the United States and Canada.
ABT-751 is in Phase 2 development. Four Phase 2 studies have been completed, and no active trials are currently recruiting. The compound has not been approved by the FDA for any indication and remains investigational.
ABT-751 has been evaluated in four completed Phase 2 trials: NCT00073151 in non-small cell lung cancer, NCT00073138 in colorectal cancer, NCT00073112 in renal cell cancer, and NCT00063102 in recurrent breast cancer after taxane therapy. All were uncontrolled, non-randomized studies conducted in the United States, with the renal cell trial also including sites in Canada.
No. ABT-751 is a distinct small molecule tubulin inhibitor developed by Abbott Laboratories. It is not the same compound as combretastatin or other tubulin-binding agents, and it has its own ChEMBL identifier, CHEMBL20684.